A remarkable case published in Frontiers in Neuroscience in May 2026 is forcing researchers to reconsider what “lost” function may actually mean in advanced Alzheimer’s disease.

An 80-something Japanese-American woman had lived with Alzheimer’s for approximately 10 years. For the previous five, her decline had been profound: predominantly one-word speech, chronic urinary incontinence, impaired mobility, difficulty swallowing, executive dysfunction, little spontaneous interaction and severe dependence on caregivers. 

Then she was given 5 grams of psilocybin-containing Enigma mushrooms under supervision.

What followed was extraordinary. Nineteen hours later, she began talking.

The initial response was intense. She experienced profuse sweating, suspected hyperthermia and a prolonged deep sleep-like state. And approximately 19 hours after taking the mushrooms, she spontaneously awakened and began speaking autobiographically for roughly four hours - after years of predominantly monosyllabic speech. 

The improvements continued over the following days.

By Day 1, she was more alert and recognizing family. By Day 2, she was walking independently. By Days 2–3, she was dressing herself and spontaneously initiating activities.

Then came one of the most remarkable changes: her diapers remained dry, including overnight, after more than five years of chronic urinary incontinence.

By Days 6–7, she was demonstrating contextual memory, sustained eye contact, reciprocal smiling and greater social engagement. 

And these weren’t simply effects occurring while she was under the influence.

One month later, she remained continent and functionally improved compared with her baseline. 

Then researchers gave her 3 grams

Because meaningful improvements persisted, she underwent a second supervised session one month later - this time with 3 grams of psilocybin-containing mushrooms.

Again, researchers saw changes.

During the second session she was substantially more verbal. She described emotionally positive imagery of surfing with her son on a peaceful island. Researchers observed greater facial expression and emotional reciprocity, spontaneous humor and improved agility while walking. 

The sequence is what makes the case so fascinating:

Advanced dementia → 5 grams → dramatic improvements in language, memory, mobility, continence and social interaction → some improvements persisting one month → 3 grams → renewed increases in speech, emotion, humor and movement.

The authors are emphatic that this does not prove Alzheimer’s was reversed. There was only one patient, no placebo group, no standardized cognitive testing, and her Alzheimer’s diagnosis lacked biomarker confirmation. 

But they raise a fascinating possibility: some functional capacity may remain inside a severely neurodegenerating brain and become temporarily accessible when brain networks are altered.

And that’s where the science surrounding psychedelics and microdosing becomes particularly interesting.

Could Microdosing Protect the Aging Brain?

First, an important distinction: the woman above was not microdosing. Five grams and three grams of mushrooms are substantial doses.

Microdosing refers to taking much smaller, sub-hallucinogenic amounts.

And as of August 2026, no controlled human study has demonstrated that microdosing psilocybin prevents, slows or reverses Alzheimer’s disease.

But researchers have been proposing precisely this line of investigation for years because psychedelics interact with several biological processes implicated in Alzheimer’s.

1. Scientists have specifically proposed microdosing for Alzheimer’s

A 2020 peer-reviewed review titled Psychedelics as a Treatment for Alzheimer’s Disease Dementia examined psilocybin and LSD specifically in relation to dementia.

The authors argued that psychedelics deserve investigation because of their potential effects on neurogenesis, neuroplasticity and neuroinflammation, focusing particularly on microdosing in early Alzheimer’s. 

That doesn’t demonstrate efficacy - but it establishes that microdosing for Alzheimer’s is a genuine scientific hypothesis, not simply an internet wellness trend.

2. We actually have a controlled microdosing study in older adults

One of the most relevant human studies involved 48 healthy older adults with an average age of 62.9. In the randomized, double-blind, placebo-controlled trial, participants received either placebo or 5, 10 or 20 micrograms of LSD every four days for six doses over 21 days. The low doses were generally well tolerated, and researchers found no impairment in cognition, balance or proprioception.

The authors concluded that the results supported further clinical development of low-dose LSD for the treatment and prevention of Alzheimer’s disease. 

Again: they did not demonstrate that LSD prevented Alzheimer’s. The participants didn’t have Alzheimer’s, and the trial lasted only 21 days. But it provided an important early safety signal for repeated low-dose psychedelic exposure in older people.

3. Psilocybin microdosing itself has been tested - but not for Alzheimer’s

A double-blind, placebo-controlled study investigated 0.5 grams of dried psilocybin mushrooms in 34 people who were beginning a microdosing practice.

The active dose produced detectable subjective effects, but the study did not establish the dramatic cognitive benefits commonly attributed to microdosing. In fact, some apparent benefits depended on participants correctly identifying whether they had received psilocybin or placebo. 

This is an important counterweight to the enthusiasm surrounding microdosing: human microdosing evidence remains mixed, and expectation/placebo effects are difficult to separate from pharmacology.

So why are Alzheimer’s researchers still interested?

Because the underlying biology is compelling.

Psilocybin appears to make the brain more plastic

Psychedelics activate the serotonin 5-HT2A receptor, but their effects extend far beyond simply changing serotonin levels.

Preclinical research has demonstrated increased dendritic growth, synaptic remodeling and structural and functional neural plasticity following psychedelic exposure. The 2026 Alzheimer’s case report specifically points to this research as one potential mechanism worth investigating. 

That matters because Alzheimer’s involves catastrophic loss of synaptic function.

If surviving neurons can strengthen connections, reorganize networks or create alternative communication pathways, researchers want to know whether some function could potentially be preserved—or temporarily recovered.

Psilocybin can reorganize entire brain networks

A major 2024 Nature study repeatedly scanned human brains before, during and after 25 mg of psilocybin.

Psilocybin profoundly desynchronized brain activity and reduced the normal separation between established brain networks. Some connectivity changes involving the hippocampus - the structure crucial to memory - persisted for weeks. 

This gives us a possible way to think about the 80-something-year-old woman’s experience.

Alzheimer’s unquestionably destroys neurons.

But perhaps some information isn’t completely erased. Instead, surviving networks may become increasingly unable to communicate with one another or retrieve stored information.

The authors of her case propose that psilocybin-induced network reorganization might temporarily allow residual neural systems to reintegrate. In other words, perhaps psilocybin isn’t recreating the memory. Perhaps, in some circumstances, it is helping the brain reach it again.

Then there is neuroinflammation Alzheimer’s isn’t simply a disease of amyloid plaques and tau. Chronic activation of the brain’s immune cells and neuroinflammatory signaling are deeply involved in neurodegeneration.

The 2020 Alzheimer’s psychedelic review highlighted the potential anti-inflammatory properties of serotonergic psychedelics as another reason low doses deserve investigation. 

This creates an intriguing microdosing hypothesis: Could repeated, very small psychedelic doses influence 5-HT2A signaling, inflammation and plasticity without requiring repeated full psychedelic experiences?

We don’t know. But that is fundamentally different from claiming microdosing already prevents Alzheimer’s.

What about synaptic density? Scientists are now testing it directly.

One of the most interesting Alzheimer-adjacent psilocybin trials is studying people with amnestic mild cognitive impairment, a condition that can precede Alzheimer’s dementia.

Researchers are using PET imaging to measure synaptic vesicular density before and after psilocybin. Participants receive two 25-mg psilocybin doses one week apart or placebo, with cognitive testing and brain imaging afterward.

The investigators are explicitly asking whether psilocybin increases measurable synaptic density - and whether any increase correlates with improved cognition. 

This isn’t microdosing either. But it’s an extremely important experiment because it moves the question beyond subjective reports:

Can psilocybin produce measurable changes at the synapse in an aging brain already showing cognitive impairment?

And then came the longevity study

In 2025, researchers reported another surprising discovery.

Human cells treated with psilocin - the active metabolite of psilocybin - remained viable and proliferative substantially longer.

Depending on concentration and cell type, researchers reported approximately 29%, 51% and 57% extensions in cellular lifespan in their experimental models. They also observed reduced oxidative stress, delayed cellular senescence, increased SIRT1 and preservation of telomere length. 

Then researchers gave psilocybin to aged mice.

At the end of the experiment, 80% of psilocybin-treated mice were alive compared with 50% of control animals. 

That does not mean psilocybin extends human lifespan or prevents Alzheimer’s. These are cells and mice, not clinical outcomes in humans.

But it suggests psychedelic biology may intersect with pathways involved in cellular aging, oxidative stress and resilience - which makes the neurodegeneration question even more intriguing.

So could microdosing eventually prevent Alzheimer’s?

The scientifically accurate answer today is: Possibly - but we don’t know yet.

There is a biologically plausible argument worth testing. Psychedelics can promote neural plasticity in experimental models, dramatically reorganize human brain networks, interact with inflammatory signaling, and are now being investigated for their effects on synaptic density in mild cognitive impairment. Low-dose LSD has also been demonstrated to be tolerable in a short controlled trial of older adults. 

But there is a crucial missing piece:

Nobody has yet shown in a long-term randomized human trial that microdosing psilocybin or LSD reduces someone’s risk of developing Alzheimer’s.

Nor has microdosing been proven to remove amyloid, reduce tau, prevent progression from mild cognitive impairment to Alzheimer’s or reverse established dementia.

The science is promising enough to investigate - but not strong enough to prescribe.

And the dramatic 2026 case shouldn’t be treated as a DIY protocol. The woman’s first high-dose experience included suspected hyperthermia, profuse sweating and profound somnolence, demonstrating why experimenting with psychedelics in elderly people with dementia can carry substantial risk. 

The question this woman leaves us with - and perhaps the most profound part of her story isn’t that psilocybin “cured Alzheimer’s.” Because it didn’t.

It’s that after approximately five years of profound dysfunction, her speech returned. Autobiographical memories surfaced. She walked independently. She dressed herself. She smiled and interacted. Continence returned and persisted for a month. Then, after a second 3-gram session, researchers again observed increased speech, humor, emotion and mobility. 

That forces us to ask a very different question:

When someone with Alzheimer’s can no longer reach their memories, does that always mean those memories are gone? Or could some of the person still be there - inside, surviving neural networks that can no longer communicate normally?

And if psychedelics can alter those networks, promote plasticity and potentially influence inflammatory and aging pathways, could carefully designed psychedelic medicines someday help us protect the brain before those connections disappear?

We don’t know yet.

But that may be one of the most fascinating questions emerging in Alzheimer’s research today.

This article is for educational purposes only and is not medical advice. Psilocybin and LSD are legally restricted in many jurisdictions, and neither psychedelic microdosing nor high-dose psilocybin is an established treatment or prevention strategy for Alzheimer’s disease.